There’s a lot of interest in the potential for γδ T cells for cancer immunotherapy with multiple US, UK and EU companies already active in the area, not to mention the Chinese too.
Now that we have a grounding in the science behind what role γδ T cells play in our immune system, what they ‘see’ and do, we can better consider how companies are translating basic research into therapeutics.
In this third post in our mini-series, we’re taking a closer look at the emerging new product development landscape.
This post is not intended to be a definitive analysis or report on the whole γδ T cell therapy landscape, instead we’ve chosen to highlight a few leading companies and use them as examples to illustrate different translational approaches that are being investigated. A report on developments in China will follow separately tomorrow.
Some companies are looking at adoptive cell therapy, others have monoclonal antibodies or bispecific antibodies in development.